This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: June 30, 2016
Last updated: July 18, 2017
Last verified: July 2017
Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

Condition Intervention
Neoplasms Carcinoma, Non-Small-Cell Lung Drug: crizotinib

Study Type: Expanded Access     What is Expanded Access?
Official Title: Crizotinib (Xalkori (Registered)) Expanded Access Protocol For The Treatment Of Japanese Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Ros1 Oncogene

Resource links provided by NLM:

Further study details as provided by Pfizer:

Intervention Details:
    Drug: crizotinib
    Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic.
  • Positive for translocation or inversion events involving the ROS1 gene as determined by protocol defined test.
  • ECOG performance status 0 to 2.
  • Adequate organ function
  • Patients with brain metastases are eligible if neurologically stable for at least 2 weeks and have no ongoing requirement for corticosteroids.
  • Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of crizotinib.

Exclusion Criteria:

  • Currently receiving crizotinib or any investigational products.
  • Prior therapy specifically directed against ROS1 fusion genes including crizotinib.
  • Carcinomatous meningitis or leptomeningeal disease.
  • Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function.
  • Ongoing uncontrolled congestive heart failure (CHF) and any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack.
  • Ongoing cardiac dysrhythmias of CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QTc more than 480 msec.
  • History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.
  • Pregnant female patients; breastfeeding female patients.
  • Use of drugs or foods including known potent CYP3A4 inhibitors, known potent CYP3A4 inducers and CYP3A4 substrates with narrow therapeutic indices
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02824094

Aichi cancer center central hospital
Nagoya, Aichi, Japan, 464-8681
National Cancer Center Hospital East
Kashiwa, Chiba, Japan, 277-8577
Hyogo Cancer Center
Akashi, Hyogo, Japan, 673-8558
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan, 135-8550
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT02824094     History of Changes
Other Study ID Numbers: A8081064
Study First Received: June 30, 2016
Last Updated: July 18, 2017

Keywords provided by Pfizer:
Expanded Access Protocol

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017